These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 3981950

  • 1. [Use of low molecular-weight heparin in hemodialysis patients].
    Schrader J, Rieger J, Müschen H, Stibbe W, Köstering H, Kramer P, Scheler F.
    Klin Wochenschr; 1985 Jan 15; 63(2):49-55. PubMed ID: 3981950
    [Abstract] [Full Text] [Related]

  • 2. Low molecular weight heparin in hemodialysis and hemofiltration patients.
    Schrader J, Valentin R, Tönnis HJ, Hildebrand U, Stibbe W, Armstrong VW, Kandt M, Köstering H, Quellhorst E.
    Kidney Int; 1985 Nov 15; 28(5):823-9. PubMed ID: 3936965
    [Abstract] [Full Text] [Related]

  • 3. Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration.
    Schrader J, Stibbe W, Armstrong VW, Kandt M, Muche R, Köstering H, Seidel D, Scheler F.
    Kidney Int; 1988 Apr 15; 33(4):890-6. PubMed ID: 2838681
    [Abstract] [Full Text] [Related]

  • 4. Monitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assay.
    Harenberg J, Haaf B, Dempfle CE, Stehle G, Heene DL.
    Nephrol Dial Transplant; 1995 Apr 15; 10(2):217-22. PubMed ID: 7753456
    [Abstract] [Full Text] [Related]

  • 5. Comparison of unfractionated heparin and low molecular weight heparin during long-term use in chronic haemodialysis and haemofiltration patients.
    Schrader J, Kandt M, Zürcher C, Köstering H, Scheler F.
    Haemostasis; 1986 Apr 15; 16 Suppl 2():48-58. PubMed ID: 3091459
    [Abstract] [Full Text] [Related]

  • 6. Use of low-dose low molecular weight heparin in hemodialysis.
    Lai KN, Wang AY, Ho K, Szeto CC, Li M, Wong LK, Yu AW.
    Am J Kidney Dis; 1996 Nov 15; 28(5):721-6. PubMed ID: 9158210
    [Abstract] [Full Text] [Related]

  • 7. Low molecular weight heparin versus standard heparin. A long-term study in hemodialysis and hemofiltration patients.
    Schrader J, Stibbe W, Kandt M, Warneke G, Armstrong V, Müller HJ, Scheler F.
    ASAIO Trans; 1990 Nov 15; 36(1):28-32. PubMed ID: 2155017
    [Abstract] [Full Text] [Related]

  • 8. Use of single dose low-molecular-weight heparin in long hemodialysis.
    Lai KN, Ho K, Li M, Szeto CC.
    Int J Artif Organs; 1998 Apr 15; 21(4):196-200. PubMed ID: 9649059
    [Abstract] [Full Text] [Related]

  • 9. Ratios of anti-factor Xa to antithrombin activities of heparins as determined in recalcified human plasma.
    Schoen P, Lindhout T, Hemker HC.
    Br J Haematol; 1992 Jun 15; 81(2):255-62. PubMed ID: 1322691
    [Abstract] [Full Text] [Related]

  • 10. Effect of switching unfractionated heparin to low-molecular-weight heparin on serum potassium in hemodialysis patients.
    Ezzatzadegan Jahromi S, Mahmoodi MS, Behroozi F, Roozbeh J, Emamghoreishi F.
    Iran J Kidney Dis; 2014 Nov 15; 8(6):475-80. PubMed ID: 25362223
    [Abstract] [Full Text] [Related]

  • 11. Lipoprotein lipase responds similarly to tinzaparin as to conventional heparin during hemodialysis.
    Mahmood D, Grubbström M, Lundberg LD, Olivecrona G, Olivecrona T, Stegmayr BG.
    BMC Nephrol; 2010 Dec 06; 11():33. PubMed ID: 21129229
    [Abstract] [Full Text] [Related]

  • 12. Beneficial effect of low molecular weight heparin on the hemodialysis model in dogs.
    Hamano S, Komatsu H, Ikeda S, Takahashi K, Oguma Y, Sakuragawa N.
    Thromb Res; 1989 Aug 15; 55(4):439-49. PubMed ID: 2554525
    [Abstract] [Full Text] [Related]

  • 13. [Effects of low molecular weight heparin (FR-860) on coagulative and fibrinolytic activities].
    Hamano S, Kinukawa M, Komatsu H, Ikeda S, Sakuragawa N.
    Nihon Yakurigaku Zasshi; 1989 Oct 15; 94(4):243-9. PubMed ID: 2613105
    [Abstract] [Full Text] [Related]

  • 14. Heparin and its biocompatibility.
    Stiekema JC.
    Clin Nephrol; 1986 Oct 15; 26 Suppl 1():S3-8. PubMed ID: 2435441
    [Abstract] [Full Text] [Related]

  • 15. Protamine neutralization of the release of tissue factor pathway inhibitor activity by heparins.
    Harenberg J, Siegele M, Dempfle CE, Stehle G, Heene DL.
    Thromb Haemost; 1993 Dec 20; 70(6):942-5. PubMed ID: 8165616
    [Abstract] [Full Text] [Related]

  • 16. [Antithrombotic effects of low molecular weight heparin (FR-860) in rabbits].
    Hamano S, Komatsu H, Ikeda S, Sakuragawa N.
    Nihon Yakurigaku Zasshi; 1989 Oct 20; 94(4):237-42. PubMed ID: 2613104
    [Abstract] [Full Text] [Related]

  • 17. The pharmacological profile of the low molecular weight heparin 21-23 in man: anticoagulant, lipolytic and protamine reversible effects.
    Harenberg J, Stehle G, Dempfle CE, von Hodenberg E, Heene DL.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989 Oct 20; 116(6):967-80. PubMed ID: 2483715
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. The Heparin Study in Internal Medicine Group.
    Harenberg J, Roebruck P, Heene DL.
    Haemostasis; 1996 Oct 20; 26(3):127-39. PubMed ID: 8738587
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.